Editorial Office Notes
RES-15-707.R1
ORIGINAL ARTICLE
Received 8 September 2015
Invited to revise 14 October 2015
Revised 4 December 2015
Accepted 26 December 2015
Associate Editor: Conroy Wong
This is the author manuscript accepted for publication and has undergone full peer review but has
not been through the copyediting, typesetting, pagination and proofreading process, which may
lead to differences between this version and the Version of Record. Please cite this article as doi:
10.1111/resp.12773
1
This article is protected by copyright. All rights reserved.
Telehealth to improve asthma control in pregnancy: a randomised controlled trial
Elida Zairina, MPH1,2, Michael J Abramson, PhD3,4, Christine F McDonald, PhD5, Jonathan
Li, PhD6, Thanuja Dharmasiri, BSc6, Kay Stewart, PhD1, Susan P Walker, PhD7,8, Eldho
Paul, MSc3,9, Johnson George, PhD1
1
Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia
2
Dept of Pharmacy Practice, Faculty of Pharmacy, Airlangga University, Surabaya, East
Java, Indonesia
3
Dept of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria,
Australia
4
Allergy, Immunology & Respiratory Medicine, the Alfred Hospital, Melbourne, Victoria,
Australia
5
Dept of Respiratory and Sleep Medicine, the Austin Hospital, Heidelberg, Victoria,
Australia
6
Dept of Electrical and Computer Systems Engineering, Faculty of Engineering, Monash
University, Clayton, Victoria, Australia
7
Department of Maternal Fetal Medicine, Mercy Hospital for Women, Melbourne, Australia
8
Department of Obstetrics and Gynaecology, University of Melbourne, Victoria, Australia
9
Department of Clinical Haematology, the Alfred Hospital, Melbourne, Victoria, Australia
2
This article is protected by copyright. All rights reserved.
Correspondence:
Johnson George, PhD
Faculty of Pharmacy and Pharmaceutical Sciences
Centre for Medicine Use and Safety
Monash University (Parkville Campus)
381 Royal Parade, Parkville, VIC 3052, Australia
Email: Johnson.George@monash.edu
Summary at a Glance:
This study evaluated the efficacy of a telehealth program, supported by a handheld
respiratory device for optimising asthma management in pregnant women. At the end of the
study, participants in the intervention group showed greater improvement in asthma control
and asthma-related quality of life than the control group.
Abbreviations:
APGAR, Activity Pulse Grimace Appearance Respiration; ACQ, Asthma Control
Questionnaire; BMI, Body Mass Index; FEV1, Forced expiratory volume in 1 second; FEV6,
Forced expiratory volume in 6 seconds; ICS, Inhaled corticosteroid; LABA, Long-acting beta
agonist; mAQLQ, mini Asthma Quality of Life Questionnaire; MCID, Minimum clinically
important difference; SABA, Short-acting beta agonist
3
This article is protected by copyright. All rights reserved.
ABSTRACT
Background and objective: Poorly controlled asthma during pregnancy is hazardous for
both mother and fetus. Better asthma control may be achieved if patients are involved in
regular self-monitoring of symptoms and self-management according to a written asthma
action plan (WAAP). Telehealth applications to optimise asthma management and outcomes
in pregnant women have not yet been evaluated. This study evaluated the efficacy of a
telehealth program supported by a handheld respiratory device in improving asthma control
during pregnancy.
Methods: Pregnant women with asthma (n=72) from two antenatal clinics in Melbourne,
Australia were randomised to one of two groups: 1) intervention – involving a telehealth
program (Management of Asthma with Supportive Telehealth of Respiratory function in
Pregnancy [MASTERY©]) supported by a handheld respiratory device and an Android smart
phone application (Breathe-easy©) and WAAP; or 2) control – usual care. The primary
outcome was change in asthma control at 3 and 6 months (prenatal). Secondary outcomes
included changes in quality of life and lung function, and perinatal/neonatal outcomes.
Results: At baseline, participants’ mean (±SD) age was 31.4±4.5 years and gestational age
16.7±3.1 weeks. At six months, the MASTERY group had better asthma control (p=0.02) and
asthma-related quality of life (p<0.01) compared to usual care. There were no significant
differences between groups in lung function, unscheduled healthcare visits, days off
work/study, oral corticosteroid use or perinatal outcomes. Differences between groups were
not significant at three months.
Conclusion: Telehealth interventions supporting self-management are feasible and could
potentially improve asthma control and asthma-related quality of life during pregnancy.
4
This article is protected by copyright. All rights reserved.
Clinical trial registration: ACTRN 12613000800729 at www.anzctr.org.au
5
This article is protected by copyright. All rights reserved.
Keywords: asthma control, pregnant women, quality of life, telehealth
Running head: Telehealth for asthma during pregnancy
6
This article is protected by copyright. All rights reserved.
INTRODUCTION
Asthma is the most common lung condition that affects and complicates pregnancy.1, 2
Managing asthma in pregnant women is an integral part of asthma guidelines,3-5 however,
poorly controlled asthma during pregnancy still remains a major problem. It increases the
risks of pre-eclampsia, foetal growth restriction, pre-term birth and need for caesarean
delivery.6-9
Visit to medical practitioners regularly and following a written asthma action plan
(WAAP) have shown better asthma control.10 Recording daily symptoms continually as a part
of asthma self-management reduces unplanned hospitalizations and improves quality of life
in asthma patients.11-14
Early detection of exacerbations and better management of asthma exacerbations can
be achieved by home telemonitoring.11-14 Internet or mobile phone-based healthcare
interventions have been reported to have potential benefits in adults11, 14 and children13 with
asthma when compared with usual care. Mobile phone-based interventions to support asthma
management have been evaluated in several studies.14-16 However, telehealth applications to
optimise asthma management and outcomes in pregnant women have not yet been evaluated.
This study evaluated the efficacy of a telehealth program in improving asthma control
during pregnancy. We hypothesised that the intervention group (Management of Asthma with
Supportive Telehealth of Respiratory function in Pregnancy [MASTERY©]) would have
better asthma control compared to usual care.
7
This article is protected by copyright. All rights reserved.
METHODS
Study design and participants
A prospective multi-centre single-blinded randomised controlled trial (RCT) was
conducted in the antenatal clinics of two large maternity hospitals in Melbourne, Australia.
The study was registered (ACTRN 12613000800729) and was approved by the human
research ethics committees of Monash University, Mercy Hospital for Women and the Royal
Women’s Hospital. All participants provided written informed consent at the time of
enrolment.
Pregnant women with asthma aged ≥18 years, up to 20 weeks gestation and able to
communicate in English were approached. Those who self-reported use of any inhaled
bronchodilator or anti-inflammatory agent for asthma within the previous 12 months were
included. Women under specialist care for brittle/difficult asthma17 or who were not in
possession of or have not used a “smart” mobile phone were excluded.
Randomisation and group allocation
The detailed protocol has been published elsewhere.18 In brief, all consenting
participants were stratified by asthma severity based on their current asthma medications and
symptoms into two groups: intermittent-mild or moderate-severe asthma.3 Participants were
randomised to intervention (MASTERY) or control (usual care) with 1:1 allocation in
random blocks of four and six using a random allocation software19 by an independent
researcher. Randomisation results were concealed using the sealed opaque envelope
technique. Participation of the women in the study is summarised in Figure 1.
8
This article is protected by copyright. All rights reserved.
9
This article is protected by copyright. All rights reserved.
Intervention and control group
Intervention: MASTERY group
Participants allocated to MASTERY were provided with a COPD-6® (Vitalograph
Ltd, Ennis, Ireland) to measure their lung function (FEV1 and FEV6) daily and a specifically
designed Breathe-easy© application installed on a loaned “smart” mobile phone to record
asthma symptoms and asthma medication usage weekly. Participants were also prompted to
follow an individualised WAAP specifically developed by the study team as part of the
intervention package. An automated feedback message regarding her asthma status was sent
weekly based on the Breathe-easy© algorithm that was based on National Asthma Council3
and Global Initiative for Asthma (GINA) guidelines.5 All data were transmitted automatically
to a central server to which the researchers, participants and their health professionals had
secure access. Participants’ health professionals were contacted by one of the researchers, a
trained asthma educator (EZ), if any medication changes or unscheduled asthma-related visits
were needed.
Control: Usual care group
Control group received usual medical care from their health professionals including
regular antenatal visits depending on pregnancy stage and presence of any complications. A
summary of the “Asthma and Pregnancy” brochure from the NAC, which explained asthma
in pregnancy, including first aid and an emergency assistance number to call for any concerns
regarding asthma, was given to participants in both groups.
Outcome measures
10
This article is protected by copyright. All rights reserved.
Change in asthma control as measured by the 7-item Asthma Control Questionnaire
(ACQ-7) at 3 and 6 months was the primary outcome.20 Juniper’s mini Asthma Quality of
Life Questionnaire (mAQLQ) score,21 lung function (FEV1 and FEV6), self-reported
exacerbations, asthma-related health visits, days off work/study related to asthma and oral
corticosteroid use were measured as the secondary outcomes. All these measures were
conducted prenatally.
Perinatal outcomes were development of any antenatal complications such as
gestational diabetes, hypertensive disorders of pregnancy, postpartum haemorrhage, and
foetal growth restriction, mode of delivery and gestational age of baby at delivery.
Neonatal outcomes included birth weight centile, birth length, head circumference,
and Appearance Pulse Grimace Activity and Respiratory (APGAR) scores at 1 and 5 minutes
after delivery. Birth weight centiles were calculated using www.gestation.net/grow-au.aspx,
which adjusted for maternal characteristics including height, weight, ethnicity, parity and
foetal gender.
Data collection and follow-up
At three and six months from baseline, ACQ and mAQLQ scores, asthma-related
health visits, asthma-related days off work/study, oral corticosteroid use were assessed to
allow comparisons. Perinatal outcomes data were collected shortly after delivery by
reviewing medical records. The outcome assessors doing follow-ups at three and six months
were masked to participant group allocation.
Sample size
11
This article is protected by copyright. All rights reserved.
Using a standard deviation in ACQ score of 0.66,22, 23 we estimated that a sample size
of 28 in each arm would have 80% power with a two-sided 5% significance level to detect
the minimal clinically important difference (MCID) in ACQ score of 0.5 or more between
groups.20 To allow for 25% attrition, 36 participants were required in each arm.
Statistical analysis
The primary analysis was performed according to the intention to treat (ITT)
principle. Baseline group characteristics were compared using Student’s t-test or MannWhitney U test or chi-square/ Fisher’s exact test as appropriate. For the primary analysis,
linear regression models were fitted to compare changes in ACQ scores at three and six
months adjusting for baseline scores. We also compared the proportion of participants whose
ACQ score improved more than 0.5 (MCID) over the study period, and the proportions in
whom asthma remained “not well controlled” (ACQ score 1.5 or greater) or “well controlled”
(ACQ score less than 1.5) at each time point.24 Secondary outcomes were summarised using
descriptive statistics and analyses performed as described above. All analyses were
performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and SPSS version 19.0
(IBM SPSS Statistics for Windows, Armonk, NY).
12
This article is protected by copyright. All rights reserved.
RESULTS
Seventy two pregnant women with asthma (38 and 34 from the two hospitals), mean
(±SD) age 31.4±4.5 years, were enrolled in the study. The groups had similar baseline
characteristics (Table 1), regardless of place of recruitment. The mean (±SD) gestational age
(in weeks) at baseline, 3 months and 6 months was 16.7±3.1, 27.4±1.3 and 36.5±0.6. No
significant difference in gestational age was observed between the groups. The majority had
moderate to severe asthma (58%). Inhaled corticosteroid/long-acting beta agonist
(ICS/LABA) combinations were the regular asthma medication for almost half of them. The
mean ACQ scores, mAQLQ scores and lung function for MASTERY and usual care groups
matched well.
Changes in ACQ score from baseline to 3 months (mean ±SE) for MASTERY and
usual care groups were -0.01±0.11 and 0.16±0.09, respectively. At six months, the changes in
ACQ score in the two groups from baseline were -0.30±0.11 and 0.06±0.10, respectively; and
the mean difference between groups was significant (p=0.02) (Table 2). Participants in the
MASTERY group also had clinically significant improvements (MCID > 0.5) in their quality
of life at six months when compared with the usual care group (p=0.002) (Table 2). Changes
in FEV1, FEV1% and FEV1/FEV6 from baseline to both three and six months between the
groups were not significant (Table 2).
Figures 2(A) and 2 (B) show changes in ACQ and mAQLQ scores, respectively, in
the two groups between baseline and both three and six months. At six months, the
MASTERY group had a higher proportion of participants with well-controlled asthma (ACQ
<1.5) than the control group (82% vs 58%, p=0.03). Compared to the control group,
MASTERY group also had more participants with a clinically significant (i.e. change in
13
This article is protected by copyright. All rights reserved.
scores greater than the MCID) improvement in ACQ (39% vs 19%; p =0.07) and mAQLQ
scores (36% vs 19%; p =0.12), but the differences were not statistically significant.
At 6 months, the MASTERY group self-reported fewer asthma symptoms requiring a
reliever in the previous three months (MASTERY [n=1] vs control [n=18], p<0.01). Only one
control participant had an unscheduled health visit related to asthma. One participant from the
MASTERY and two from the control group were prescribed an oral corticosteroid. One
participant in each group reported days off work/study related to asthma.
The perinatal outcomes including neonatal outcomes, delivery data and complications
at the end of the study were similar in both groups (Table 3). Differences between the groups
in normal vaginal delivery (MASTERY=58%, usual care=47%; p =0.39) and emergency
caesarean (MASTERY=12%, usual care=17%; p =0.74) did not reach statistical significance.
No significant differences in neonatal outcomes or pregnancy complications were observed
between the groups.
14
This article is protected by copyright. All rights reserved.
DISCUSSION
A telehealth intervention supported by a mobile application, self-monitoring device
and use of an individualized WAAP improved self-management of asthma in pregnancy.
Change in asthma control was statistically significant in the MASTERY (telehealth) group at
6 months, but the mean change in ACQ score failed to reach the MCID. At 6 months, better
asthma-related quality of life, and fewer self-reported exacerbations were observed in the
MASTERY group; however, changes in lung function between groups were not significant.
This study also established the role of WAAP guided self-management in optimising asthma
control in pregnancy. Assessing asthma symptoms, monitoring lung function regularly and
establishing individual WAAP are components of asthma self-management according to
GINA and NAC.3, 25 Since pregnancy may alter the severity of asthma unpredictably,26
pregnant women with asthma should be encouraged to have self-management plans with
close monitoring of asthma symptoms/control to prevent exacerbations during pregnancy.
A Cochrane Review of self-management education and regular practitioner review
has found that monitoring asthma severity and the use of WAAP could reduce the frequency
of asthma exacerbations, optimise asthma medication use and decrease the cost of asthma
management.10 Monitoring asthma regularly using objective measures of lung function
(FEV1) and asthma symptoms could improve asthma control and reduce exacerbations during
pregnancy.27 Lim et al22 showed that multidisciplinary care involving education and regular
monitoring in pregnant women with asthma could improve maternal asthma outcomes. Our
study adds further knowledge and highlights the potential role of telemonitoring of asthma in
pregnancy. Automated feedback based on an individualised WAAP may identify worsening
asthma control and prompt appropriate intervention, potentially preventing further
15
This article is protected by copyright. All rights reserved.
deterioration of asthma control without direct involvement of any health professional.
However, compared to the control group, the intervention group may have had additional
beneficial effects from the personalised WAAP that was provided as part of the intervention.
The effect of combined mobile phone and web application/software on asthma control
in adults was examined by Liu et al14 and Ryan et al.15 The intervention groups had
interactive software applications installed on participants’ mobile-phones which allowed
recording of lung function (FEV1) daily and asthma symptoms. Control groups were provided
with a written asthma diary and WAAP. Liu et al14 found that at six months, the intervention
group had better lung function and quality of life, fewer exacerbations and unplanned visits
than the control group. However Ryan et al15 did not find any significant difference in
outcomes between the study groups. Our trial included a much younger pregnant cohort, and
excluded those who were not in possession of or have not used a “smart” mobile phone.
Differences in participant characteristics (pregnant women vs ≥12 years) and the study
settings (maternity hospitals vs primary care clinics), might explain the differences in
outcomes between our study and Ryan et al17. Additionally, our usual care was less intensive
than that of Liu et al14 and Ryan et al15 and it is possible that the observed benefits in our
study resulted from the enhanced clinical care rather than the technological intervention.
Asthma self-management supported by personalised WAAP reduces severe
exacerbations, unscheduled health visits and hospitalisations.28 Studies to date have not
provided a strong evidence base to guide clinicians or policy makers on the use of mobile
phone apps for delivering asthma self-management programs.29 The Breathe-easy©
application encourages patients to manage asthma by monitoring their symptoms and lung
function regularly and provides them with instant feedback regarding their asthma control. As
16
This article is protected by copyright. All rights reserved.
part of the Breathe-easy© algorithm, we also provided individualised WAAP for the
MASTERY group. WAAP has been widely recommended as a component of asthma selfmanagement rather than stand-alone intervention.10, 30 This study showed the importance of
having an individualised WAAP as part of a self-management program for every person with
asthma; however a close collaboration between patients and their health care professionals
and feedback are required for full benefits.31, 32
Our study had some strengths and limitations. This was the first study to investigate
the role of telehealth for supporting asthma management in pregnant women. It was carried
out in the antenatal clinics of two large maternity hospitals and included participants from a
range of socio-demographic backgrounds and asthma severity. It was not possible to mask the
intervention, which may have caused potential respondent bias, however we minimised bias
by using objective assessments including spirometry (FEV1 and FEV6) and standardised
questionnaires for the 3 and 6 months follow-ups. Exacerbations self-reported by participants
might have been mild/moderate exacerbations, but no information on the amount of relievers
used was collected. However, outcome assessments were performed by trained research
assistants masked to group allocation.
The intervention was not suitable for patients with visual/hearing impairment and
those unable to operate a smart mobile phone. Women’s adherence to the advice provided
through the app was not assessed. It is unknown to what extent general practitioners were
involved in monitoring their patients’ asthma. The place of mobile technology in clinical care
might depend on whether it is cost effective for enhancing “usual care” to the standards
recommended by guidelines. The study was not powered to assess the cost-effectiveness of
the MASTERY intervention compared to usual care in the study clinics. Further studies
17
This article is protected by copyright. All rights reserved.
evaluating patient adherence to feedback provided through the app, comparative assessments
of the telehealth intervention and WAAP against usual care, and cost-effectiveness analyses
of telehealth interventions are warranted.
In summary, a telehealth intervention was shown to be feasible for monitoring asthma
in pregnant women. The effects of Breathe-easy© application on asthma control, asthmarelated quality of life and exacerbations should be evaluated in larger studies, other
populations with asthma, and those with other chronic respiratory conditions such as COPD.
Acknowledgements
The authors would like to thank the study participants and staff at the Mercy Hospital for
Women and the Royal Women’s Hospital. The authors also wish to thank the Asthma
Foundation of Victoria and the National Asthma Council Australia for their assistance in
participant recruitment, Vitalograph Inc. for in-kind support, Monash Research Impact Fund
for financial support, Ms Denise Van den Bosch and Ms Jessica Webster for their help in
follow-up data collection and Ms Ann Distefano for her assistance in designing participant
written asthma action plans. JG has received in-kind support from Vitalograph, the
manufacturers of COPD-6, for this research.
Disclosure statement
18
This article is protected by copyright. All rights reserved.
MA and JG have held investigator-initiated research grants from Pfizer and Boehringer
Ingelheim for unrelated research. MA has undertaken an unrelated consultancy for Astra
Zeneca and received assistance with conference attendance from Boehringer-Ingelheim and
Sanofi. CMcD has participated in advisory boards and educational meetings for AstraZeneca,
Boehringer Ingelheim, GSK and Novartis. This research was previously presented at the
TSANZSRS Annual Scientific Meeting
2015.
19
This article is protected by copyright. All rights reserved.
REFERENCES
1
Sawicki E, Stewart K, Wong S, Leung L, Paul E, George J. Medication use for
chronic health conditions by pregnant women attending an Australian maternity hospital.
Aust N Z J Obstet Gynaecol. 2011; 51: 333-8.
2
Clifton VL, Engel P, Smith R, Gibson P, Brinsmead M, Giles WB. Maternal and
neonatal outcomes of pregnancies complicated by asthma in an Australian population. Aust N
Z J Obstet Gynaecol. 2009; 49: 619-26.
3
National Asthma Council Australia. Australian Asthma Handbook - Quick Reference
Guide, version 1.0. National Asthma Council Australia, Melbourne, 2014. Available from
[http://www.asthmahandbook.org.au]. Accessed 30 July 2015.
4
Busse WW. NAEPP Expert Panel Report: Managing Asthma During Pregnancy:
Recommendations for Pharmacologic Treatment—2004 Update. J Allergy Clin Immunol.
2005; 115: 34-46.
5
Managing asthma with comorbidities and in special populations In: Global Strategy
for Asthma Management and Prevention, From the Global Strategy for Asthma Management
and Prevention, Global Initiative for Asthma (GINA), 2015 Update. Available from
[http://www.ginaasthma.org/]. Accessed 30 July 2015.
6
Namazy JA, Murphy VE, Powell H, Gibson PG, Chambers C, Schatz M. Effects of
asthma severity, exacerbations and oral corticosteroids on perinatal outcomes. European
Respiratory Journal. 2013; 41: 1082-90.
7
Murphy VE, Wang G, Namazy JA, Powell H, Gibson PG, Chambers C, Schatz M.
The risk of congenital malformations, perinatal mortality and neonatal hospitalisation among
pregnant women with asthma: a systematic review and meta-analysis. BJOG. 2013; 120: 81222.
8
Rejno G, Lundholm C, Gong T, Larsson K, Saltvedt S, Almqvist C. Asthma during
Pregnancy in a Population-Based Study - Pregnancy Complications and Adverse Perinatal
Outcomes. PLoS One. 2014; 9: e104755.
9
Mendola P, Laughon SK, Mannisto TI, Leishear K, Reddy UM, Chen Z, Zhang J.
Obstetric complications among US women with asthma. Am J Obstet Gynecol. 2013; 208:
127 e1-8.
20
This article is protected by copyright. All rights reserved.
10
Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, Bauman A,
Hensley MJ, Walters EH. Self-management education and regular practitioner review for
adults with asthma. Cochrane Database Syst Rev. 2003: CD001117.
11
Rasmussen LM, Phanareth K, Nolte H, Backer V. Internet-based monitoring of
asthma: A long-term, randomized clinical study of 300 asthmatic subjects. J Allergy Clin
Immunol. 2005; 115: 1137-42.
12
Willems DCM, Joore MA, Hendriks JJE, Wouters EFM, Severens JL. Cost-
effectiveness of self-management in asthma: a systematic review of peak flow monitoring
interventions. Int J Technol Assess Health Care. 2006; 22: 436-42.
13
Chan DS, Callahan CW, Sheets SJ, Moreno CN, Malone FJ. An Internet-based store-
and-forward video home telehealth system for improving asthma outcomes in children. Am J
Health Syst Pharm. 2003; 60: 1976-81.
14
Liu WT, Huang CD, Wang CH, Lee KY, Lin SM, Kuo HP. A mobile telephone-based
interactive self-care system improves asthma control. Eur Respir J. 2011; 37: 310-7.
15
Ryan D, Price D, Musgrave SD, Malhotra S, Lee AJ, Ayansina D, Sheikh A,
Tarassenko L, Pagliari C, Pinnock H. Clinical and cost effectiveness of mobile phone
supported self monitoring of asthma: multicentre randomised controlled trial. BMJ. 2012;
344: e1756.
16
Van der Meer V, Bakker MJ, van den Hout WB, Rabe KF, Sterk PJ, Kievit J,
Assendelft WJ, Sont JK, Group SS. Internet-based self-management plus education compared
with usual care in asthma: a randomized trial. Ann Intern Med. 2009; 151: 110-20.
17
Asthma Australia. 2015. Asthma with a difference. Available at:
http://www.asthmaaustralia.org.au/onAIR/Asthma_with_a_difference.aspx. Accessed July
2015.
18
Zairina E, Abramson MJ, McDonald CF, Li J, Dharmasiri T, Stewart K, Walker SP,
Paul E, George J. Study protocol for a randomised controlled trial evaluating the efficacy of a
telehealth program - management of asthma with supportive telehealth of respiratory function
in pregnancy (MASTERY). BMC Pulm Med. 2015; 15: 84.
19
Saghaei M. Random allocation software for parallel group randomized trials. BMC
medical research methodology. 2004; 4: 26.
21
This article is protected by copyright. All rights reserved.
20
Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and
validation of a questionnaire to measure asthma control. Eur Respir J. 1999; 14: 902-7.
21
Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of
the Mini Asthma Quality of Life Questionnaire. European Respiratory Journal. 1999; 14: 328.
22
Lim AS, Stewart K, Abramson MJ, Walker SP, Smith CL, George J.
Multidisciplinary Approach to Management of Maternal Asthma (MAMMA): a randomized
controlled trial. Chest. 2014; 145: 1046-54.
23
Goeman D, Jenkins C, Crane M, Paul E, Douglass J. Educational intervention for
older people with asthma: a randomised controlled trial. Patient Educ Couns. 2013; 93: 58695.
24
Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying 'well-controlled' and 'not
well-controlled' asthma using the Asthma Control Questionnaire. Respir Med. 2006; 100:
616-21.
25
Braman SS. The global burden of asthma. Chest. 2006; 130: 4S-12S.
26
Schatz M, Harden K, Forsythe A, Chilingar L, Hoffman C, Sperling W, Zeiger RS.
The course of asthma during pregnancy, post partum, and with successive pregnancies: A
prospective analysis. J Allergy Clin Immunol. 1988; 81: 509-17.
27
Zairina E, Stewart K, Abramson MJ, George J. The effectiveness of non-
pharmacological healthcare interventions for asthma management during pregnancy: a
systematic review. BMC Pulm Med. 2014; 14: 46.
28
Pinnock H, Thomas M. Does self-management prevent severe exacerbations? Curr
Opin Pulm Med. 2015; 21: 95-102.
29
Marcano-Belisario JS GG, Huckvale K, Gunn LH, Car J. . Smartphone and tablet self-
management apps for asthma (Protocol). 2012.
30
Gibson PG, Powell H, Coughlan J, Wilson AJ, Hensley MJ, Abramson M, Bauman
A, Walters EH. Limited (information only) patient education programs for adults with
asthma. Cochrane Database Syst Rev. 2002: CD001005.
31
Gibson PG. Asthma action plans: use it or lose it. Primary Care Respiratory Journal.
2004; 13: 17-8.
22
This article is protected by copyright. All rights reserved.
32
Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of
the key components. Thorax. 2004; 59: 94-9.
23
This article is protected by copyright. All rights reserved.
Figure legends
Figure 1. CONSORT diagram of participant flow
Assessedfor
for eligibility
eligibility (n=
Assessed
(n=157)
157)
Enrolment
Randomised (n=
Randomiszed
(n=72)
72)
Intervention (MASTERY group)
(n= 36)
Allocation
Excluded (n= 85)
• Not meeting inclusion criteria (n= 50)
(Not taking asthma medication in the last
12 months (n=15), only had childhood
asthma (n=17), only had exercise
induced bronchoconstriction (n=18))
• Declined to participate (n= 28)
• Other reasons (n= 7)
Control (Usual care group)
(n= 36)
Follow-Up
3-month follow-up completed (n=33)
• Lost to follow-up (not contactable) (n=1)
• Discontinued (withdrawal) (n=2)
3-month follow-up completed (n=36)
6-month follow-up completed (n=35)
• Discontinued (withdrawal) (n=1)
6-month follow-up completed (n=32)
• Lost to follow-up (not contactable) (n=1)
• Discontinued (withdrawal) (n=3)
Analysis
Analysed (n= 33)*
Excluded from analysis inclusive of lost to follow
up and withdrawals (valid for only per protocol
analysis) (n= 4)
Analysed (n= 36)*
Excluded from analysis inclusive of lost to follow
up and withdrawals (valid for only per protocol
analysis) (n= 1)
*ITT analysis:
who
hadhad
at least
one follow-up
were included
in the primary
analysis analysis
*ITT
analysis:participants
participants
who
at least
one follow-up
were included
in the primary
24
This article is protected by copyright. All rights reserved.
Figure 2. (A) Changes in ACQ scores (B) Changes in mAQLQ scores.
Data are expressed as mean ± SE
25
This article is protected by copyright. All rights reserved.
Table 1. Demographic, maternal and clinical characteristics of the study population at
baseline
MASTERY group
(n=36)
Usual care group
(n=36)
Demographic characteristics
Race
Caucasian
30 (84)
30 (84)
Asian
3 (8)
3 (8)
Other
3 (8)
3 (8)
Australian/New Zealander
30 (83)
30 (83)
Married
27 (75)
29 (81)
Full time employment
17 (47)
18 (50)
Health care/concession card holder
5 (14)
4 (11)
Possessed current asthma action plan
2 (5)
1 (3)
Level of education
High school graduate
5 (14)
4 (11)
University graduate
6 (16)
11 (31)
Postgraduate or advanced degree
15 (42)
13 (36)
Other
10 (28)
8 (22)
Smoking status
Never
25 (69)
23 (64)
Quit pre-pregnancy
8 (22)
11 (30)
Quit during pregnancy
1 (3)
1 (3)
Currently smoking
2 (5)
1 (3)
Maternal characteristics
Age (years)1
31.1± 4.7
31.8 ± 4.3
Height 1
164.0 ± 5.4
161.7 ± 7.1
Weight (kg)1
78.9 ± 21.6
70.8 ± 11.1
BMI (kg/m2)1
29.3 ± 7.4
27.6 ± 3.9
Gestational age (weeks)1
16.5 ± 2.9
16.2 ± 2.9
Primigravid
16 (44)
15 (42)
Other medical conditions
Anxiety/depression
10 (28)
10 (28)
Thyroid disorder
4 (11)
2 (6)
Clinical characteristics
Duration of asthma [years]2
26.5 [20.50 – 30]
25.5 [20 – 30]
Asthma severity
Intermittent to Mild
15 (42)
15 (42)
Moderate to Severe
21 (58)
21 (58)
Asthma medications
SABA only
15 (42)
15 (42)
ICS + SABA
3 (8)
2 (6)
ICS/LABA + SABA
18 (50)
19 (52)
FEV1 in litres3
2.7 ± 0.1
2.9 ± 0.1
FEV1% predicted 3
89.1 ± 2.3
91.6 ± 0.1
FEV1/FEV6 (%)3
80.1 ± 1.1
81.5 ± 1.0
ACQ score3
1.1 ± 0.1
1.2 ± 0.1
mAQLQ score3
5.5 ± 0.2
5.5 ± 0.2
ACQ, Asthma Control Questionnaire; BMI, Body Mass Index; mAQLQ, mini Asthma Quality of Life
Questionnaire;FEV1, Forced expiratory volume in 1 second; FEV1%, FEV1 expressed as a
percentage of the predicted value; FEV6, Forced expiratory volume in 6 seconds; ICS, inhaled
corticosteroid; LABA, long-acting beta agonist, SABA, short-acting beta agonist. Values are
26
This article is protected by copyright. All rights reserved.
presented as numbers (percentages) unless specified. 1mean ± SD, 2 median [interquartile range],
3
mean ± SE.
27
This article is protected by copyright. All rights reserved.
Table 2. Mean (±SE) change of ACQ, mAQLQ score and lung function from baseline to 3
and 6 months and the difference in mean change between groups adjusted for baseline.
Change within group
Difference between groups
adjusted for baseline
95% CI
p value
Change in
MASTERY
Usual care
Mean
outcome
group (n=33)
group (n=36)
difference
ACQ
3 months
-0.01± 0.11
0.16 ± 0.09
-0.17 ± 0.14
-0.45 to 0.12
0.26
6 months
-0.30 ± 0.11
0.06 ± 0.10
-0.36 ± 0.15
-0.66 to -0.07
0.02
mAQLQ
3 months
0.09 ± 0.14
-0.17 ± 0.13
0.27 ± 0.19
-0.09 to 0.64
0.15
6 months
0.51 ± 0.16
-0.22 ± 0.15
0.72 ± 0.22
0.29 to 1.16
0.002
FEV1
3 months
0.12 ± 0.05
0.08 ± 0.05
-0.03 ± 0.06
-0.16 to 0.09
0.63
6 months
0.11 ± 0.06
0.07 ± 0.05
-0.04 ± 0.08
-0.19 to 0.11
0.57
FEV1%
3 months
6.04 ± 1.69
1.75 ± 1.57
-4.29 ± 2.32
-8.84 to 0.25
0.07
6 months
4.27 ± 1.86
1.54 ± 1.72
-2.72 ± 2.54
-7.71 to 2.27
0.29
FEV1/FEV6
3 months
3.43 ± 1.17
0.14 ± 1.09
-3.29 ± 1.61
-6.44 to 0.14
0.05
6 months
1.53 ± 1.07
-0.56 ± 0.98
-2.08 ± 1.46
-4.94 to 0.78
0.16
ACQ, Asthma Control Questionnaire; mAQLQ, mini Asthma Quality of Life Questionnaire;FEV1, Forced
expiratory volume in 1 second; FEV1%, FEV1 expressed as a percentage of the predicted value; FEV6, Forced
expiratory volume in 6 seconds. Values are presented as mean ± SE. Decreased (negative) ACQ score suggests
asthma control improved from baseline. Increased (positive) mAQLQ score suggests QoL improved from
baseline.
28
This article is protected by copyright. All rights reserved.
Table 3. Perinatal outcome data and the comparison between the groups
MASTERY group
(n=33)
Usual care group
(n=36)
Outcome
Neonatal Data
Male
16 (49)
21 (58)
Birth weight (g)1
3434 ± 555
3447 ± 547
Length 1
49.9 ± 2.7
50.3 ± 2.3
Head circumference 1
34.3 ± 1.7
34.8 ± 2.8
APGAR score2
At 1 minute
9 [8-9]
9 [7.25 – 9]
At 5 minutes
9 [9-9]
9 [9-9]
Gestational age (weeks)1
39.1 ± 1.4
39.3 ± 1.2
Admission to NICU or SCN
1 (3)
2 (6)
Premature (< 37 weeks)
1 (3)
2 (6)
Low birth weight (<10th centile for
4 (12)
7 (19)
gestational age)
Delivery Data
Mode of Delivery
Vaginal delivery
19 (58)
17 (47)
Assisted delivery
4 (12)
7 (19)
Elective caesarean
6 (18)
6 (17)
Emergency caesarean
4 (12)
6 (17)
Complications
Gestational diabetes
3 (9)
6 (17)
Hypertensive disorders of pregnancy
2 (6)
2 (6)
Postpartum haemorrhage
1 (3)
2 (6)
Macrosomia
2 (6)
5 (14)
IUGR
1 (3)
0 (0)
APGAR, Activity Pulse Grimace Appearance, Respiration; NICU, Neonatal Intensive Care Unit;
SCN, Special Care Nursery; IUGR, Intra Uterine Growth Restrictions.
Values are presented as numbers (percentages) unless specified. 1mean ± SD, 2 median
[interquartile range]
29
This article is protected by copyright. All rights reserved.
RESP_12773_F2.jpg
This article is protected by copyright. All rights reserved.
RESP_12773_PFF.tif
This article is protected by copyright. All rights reserved.
Minerva Access is the Institutional Repository of The University of Melbourne
Author/s:
Zairina, E;Abramson, MJ;McDonald, CF;Li, J;Dharmasiri, T;Stewart, K;Walker, SP;Paul,
E;George, J
Title:
Telehealth to improve asthma control in pregnancy: A randomized controlled trial
Date:
2016-07
Citation:
Zairina, E., Abramson, M. J., McDonald, C. F., Li, J., Dharmasiri, T., Stewart, K., Walker,
S. P., Paul, E. & George, J. (2016). Telehealth to improve asthma control in pregnancy: A
randomized controlled trial. RESPIROLOGY, 21 (5), pp.867-874. https://doi.org/10.1111/
resp.12773.
Persistent Link:
http://hdl.handle.net/11343/291116